Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study

Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study

Abstract A lack of biomarkers that detect drug-induced liver injury (DILI) accurately continues to hinder early- and late-stage drug development and remains a challenge in clinical practice. The Innovative Medicines Initiative’s TransBioLine consortium comprising academic and industry partners is de...

Full description

Bibliographic Details
Main Authors: Jane I. Grove, Camilla Stephens, M. Isabel Lucena, Raúl J. Andrade, Sabine Weber, Alexander Gerbes, Einar S. Bjornsson, Guido Stirnimann, Ann K. Daly, Matthias Hackl, Kseniya Khamina-Kotisch, Jose J. G. Marin, Maria J. Monte, Sara A. Paciga, Melanie Lingaya, Shiva S. Forootan, Christopher E. P. Goldring, Oliver Poetz, Rudolf Lombaard, Alexandra Stege, Helgi K. Bjorrnsson, Mercedes Robles-Diaz, Dingzhou Li, Thi Dong Binh Tran, Shashi K. Ramaiah, Sophia L. Samodelov, Gerd A. Kullak-Ublick, Guruprasad P. Aithal, on behalf of the TransBioLine consortium
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Diagnostic and Prognostic Research
Online Access:https://doi.org/10.1186/s41512-023-00155-z

Internet

https://doi.org/10.1186/s41512-023-00155-z

Similar Items